GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Valuation Rank

Context Therapeutics (FRA:6K9) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Context Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (FRA:6K9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Valuation Rank
Comparable Companies
NTRB AZTR KALA MYMD LSTA ICU AXLA EQ COCP MBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CNTX:USA 6K9:Germany
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Website
https://www.contexttherapeutics.com
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.